Oncternal Therapeutics Inc. (ONCT) may enjoy gains as insiders got busy in the recent days


Oncternal Therapeutics Inc.’s filing revealed that its Chief Scientific Officer Kaufmann Gunnar F. acquired Company’s shares for reported $1079.0 on Jun 14. In the deal valued at $0.36 per share,3,000 shares were bought. As a result of this transaction, Kaufmann Gunnar F. now holds 94,726 shares worth roughly $ 28417.8.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Kaufmann Gunnar F. bought 25,000 shares, generating $8,745 in total proceeds. Upon buying the shares at $0.35, the Chief Scientific Officer now owns 91,726 shares.

Before that, BREITMEYER JAMES B bought 50,000 shares. Oncternal Therapeutics Inc. shares valued at $14,930 were divested by the Chief Executive Officer at a price of $0.30 per share. As a result of the transaction, BREITMEYER JAMES B now holds 196,544 shares, worth roughly $58963.2.

Oppenheimer initiated its Oncternal Therapeutics Inc. [ONCT] rating to an Outperform in a research note published on Friday, April 07, 2021; the price target was $14. PT values the company’s stock at a premium of 97.86 to its Friday closing price.

Price Performance Review of ONCT

On Friday, Oncternal Therapeutics Inc. [NASDAQ:ONCT] saw its stock jump 0.03% to $0.30. On the same session, the stock had its day’s lowest price of $0.2967, but rose to a high of $0.311. Over the last five days, the stock has lost -9.06%. Oncternal Therapeutics Inc. shares have fallen nearly -69.99% since the year began. Nevertheless, the stocks have fallen -73.21% over the past one year. While a 52-week high of $1.33 was reached on 01/18/23, a 52-week low of $0.26 was recorded on 04/10/23. SMA at 50 days reached $0.3655, while 200 days put it at $0.6434. A total of 0.26 million shares were traded, compared to the trading of 0.22 million shares in the previous session.

Levels Of Support And Resistance For ONCT Stock

The 24-hour chart illustrates a support level at 0.2942, which if violated will result in even more drops to 0.2883. On the upside, there is a resistance level at 0.3085. A further resistance level may holdings at 0.3169. The Relative Strength Index (RSI) on the 14-day chart is 40.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0192, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.56%. Stochastics %K at 9.34% indicates the stock is a buying.

How much short interest is there in Oncternal Therapeutics Inc.?

A steep rise in short interest was recorded in Oncternal Therapeutics Inc. stocks on Aug 14, 2023, dropping by -0.13 million shares to a total of 0.32 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.45 million shares. There was a decline of -39.81%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.59% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.36.

Oncternal Therapeutics Inc. [ONCT] – Who Are The Largest Shareholders?

In filings from The Vanguard Group, Inc., it is revealed that the company now owns 2,844,220 shares, or roughly 4.84% of the outstanding ONCT shares. In other words, the investor’s shares have fallen by -3,234 from its previous 13-F filing of 2847454.0. Additionally, Millennium Management LLC increased 9.98% of its stake after which the total value it holdings stand at $608,604, while BlackRock Fund Advisors reduced -12.42% of its stake to hold $0.29 million in the firm. At present, BIT Capital GmbH is holding 417,000 shares valued at $0.15 million. Geode Capital Management LLC owned 415,584 shares of the company at the time of its most recent 13F filing, worth $0.15 million.

According to FactSet, Oncternal Therapeutics Inc.’s share price will average $1.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 533.33 percent from its previous closing price of $0.30. Analysts expect Oncternal Therapeutics Inc. stock to reach the higher price of $2.50, while the lowest price estimate is $1.30. However, 5 analysts have rated ONCT stock as a Hold in their predictions for 2023.


Please enter your comment!
Please enter your name here